For example, tofersen, a 2′-MOE ASO designed to target superoxide dismutase (SOD1) for amyotrophic lateral sclerosis (ALS), recently completed phase 3 clinical trial testing and received FDA approval in April 2023 (Miller et al., 2020, 2022; FDA, 2023). The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.